Literature DB >> 15142950

Expression of mutant p193 and p53 permits cardiomyocyte cell cycle reentry after myocardial infarction in transgenic mice.

Hidehiro Nakajima1, Hisako O Nakajima, Shih-Chong Tsai, Loren J Field.   

Abstract

Previous studies have demonstrated that expression of p193 and p53 mutants with dominant-interfering activities renders embryonic stem cell-derived cardiomyocytes responsive to the growth promoting activities of the E1A viral oncoproteins. In this study, the effects of p53 and p193 antagonization on cardiomyocyte cell cycle activity in normal and infarcted hearts were examined. Transgenic mice expressing the p193 and/or the p53 dominant-interfering mutants in the heart were generated. Transgene expression had no effect on cardiomyocyte cell cycle activity in uninjured adult hearts. In contrast expression of either transgene resulted in a marked induction of cardiomyocyte cell cycle activity at the infarct border zone at 4 weeks after permanent coronary artery occlusion. Expression of the p193 dominant-interfering mutant was also associated with an induction of cardiomyocyte DNA synthesis in the interventricular septa of infarcted hearts. A concomitant and marked reduction in hypertrophic cardiomyocyte growth was observed in the septa of hearts expressing the p193 dominant-interfering transgene, suggesting that cell cycle activation might partially counteract the adverse ventricular remodeling that occurs after infarction. Collectively these data suggest that antagonization of p193 and p53 activity relaxes the otherwise stringent regulation of cardiomyocyte cell cycle reentry in the injured adult heart.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142950     DOI: 10.1161/01.RES.0000132279.99249.f4

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  29 in total

1.  Spatial variability in T-tubule and electrical remodeling of left ventricular epicardium in mouse hearts with transgenic Gαq overexpression-induced pathological hypertrophy.

Authors:  Wen Tao; Jianjian Shi; Gerald W Dorn; Lei Wei; Michael Rubart
Journal:  J Mol Cell Cardiol       Date:  2012-06-21       Impact factor: 5.000

Review 2.  Cardiac repair by embryonic stem-derived cells.

Authors:  M Rubart; L J Field
Journal:  Handb Exp Pharmacol       Date:  2006

Review 3.  Cell-based approaches for cardiac repair.

Authors:  Michael Rubart; Loren J Field
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

4.  Expression of a mutant p193/CUL7 molecule confers resistance to MG132- and etoposide-induced apoptosis independent of p53 or Parc binding.

Authors:  Joshua D Dowell; Shih-Chong Tsai; Dora C Dias-Santagata; Hidehiro Nakajima; Zhuo Wang; Wuqiang Zhu; Loren J Field
Journal:  Biochim Biophys Acta       Date:  2006-12-15

5.  Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions.

Authors:  Paul R Crisostomo; Aaron M Abarbanell; Meijing Wang; Tim Lahm; Yue Wang; Daniel R Meldrum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-22       Impact factor: 4.733

6.  Cardiomyocyte proliferation prevents failure in pressure overload but not volume overload.

Authors:  Karl Toischer; Wuqiang Zhu; Mark Hünlich; Belal A Mohamed; Sara Khadjeh; Sean P Reuter; Katrin Schäfer; Deepak Ramanujam; Stefan Engelhardt; Loren J Field; Gerd Hasenfuss
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

7.  Cardiomyocyte cell cycle activation ameliorates fibrosis in the atrium.

Authors:  Hidehiro Nakajima; Hisako O Nakajima; Klaus Dembowsky; Kishore B S Pasumarthi; Loren J Field
Journal:  Circ Res       Date:  2005-11-23       Impact factor: 17.367

Review 8.  The COP9 signalosome and cullin-RING ligases in the heart.

Authors:  Xuejun Wang; Douglas S Martin
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

Review 9.  The cardiomyocyte cell cycle.

Authors:  Pascal J E Lafontant; Loren J Field
Journal:  Novartis Found Symp       Date:  2006

10.  P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.

Authors:  Wuqiang Zhu; Wenjun Zhang; Weinian Shou; Loren J Field
Journal:  Cardiovasc Res       Date:  2014-05-08       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.